Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Other Accumulated Expenses (2016 - 2021)

Historic Other Accumulated Expenses for Sanofi (SNY) over the last 13 years, with Q4 2021 value amounting to $220.4 million.

  • Sanofi's Other Accumulated Expenses rose 487.27% to $220.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $220.4 million, marking a year-over-year increase of 487.27%. This contributed to the annual value of $228.0 million for FY2021, which is 1328.69% up from last year.
  • Latest data reveals that Sanofi reported Other Accumulated Expenses of $220.4 million as of Q4 2021, which was up 487.27% from $210.2 million recorded in Q4 2020.
  • Over the past 5 years, Sanofi's Other Accumulated Expenses peaked at $10.8 billion during Q4 2017, and registered a low of $161.3 million during Q4 2019.
  • Its 5-year average for Other Accumulated Expenses is $4.6 billion, with a median of $220.4 million in 2021.
  • Per our database at Business Quant, Sanofi's Other Accumulated Expenses surged by 219352.29% in 2017 and then crashed by 9812.8% in 2018.
  • Quarter analysis of 5 years shows Sanofi's Other Accumulated Expenses stood at $10.8 billion in 2017, then plummeted by 98.24% to $191.0 million in 2018, then fell by 15.54% to $161.3 million in 2019, then skyrocketed by 30.34% to $210.2 million in 2020, then increased by 4.87% to $220.4 million in 2021.
  • Its Other Accumulated Expenses stands at $220.4 million for Q4 2021, versus $210.2 million for Q4 2020 and $161.3 million for Q4 2019.